Medrad brought into new Bayer business unit
by
Brendon Nafziger, DOTmed News Associate Editor | March 09, 2012
Bayer HealthCare said it has folded its contrast agent injector and service subsidiary Medrad into a newly created Radiology and Interventional unit.
The new unit combines Medrad with Bayer's contrast media business. Medrad's name will be retained for the products, but the businesses have been integrated, the company said.
Although the move was announced at the European Congress of Radiology's annual meeting last week, the two groups have actually been operating as one since January 1, 2012, Karen Sutherland, a Bayer HealthCare representative, told DOTmed News.
"We had two businesses here that are successful, they're market-leading businesses. And they have an overlapping customer base. It just made sense," she said about the merger. "We can focus our efforts into this area. We can derive new innovations from the teams working together."
She stressed that this change was mostly internal and would have minimal impact on customers as customer-facing contacts would generally remain the same.
The new unit has 2,600 employees worldwide, not including other support staff, and is led by Alan Main, who leads Bayer Medical Care's division, headquartered in Tarrytown, N.Y.
Medrad makes injection systems and related products for MRI, CT, nuclear medicine and angiography, as well as catheters and MRI coils. The company also offers mutli-vendor service for ultrasound probes, CR systems and MRI coils.
Medrad was acquired by Bayer in 2006, after Bayer bought Schering AG, which had earlier acquired Medrad in the 1990s, shortly after it went public.
But Medrad's history begins in 1964, when Dr. M. Stephen Heilman, an inventor and physician who would go on to co-develop the implantable cardiac defibrillator, created in his kitchen the first Medrad device: a power injector to release contrast material at a constant flow for angiographies.
|
|
You Must Be Logged In To Post A Comment
|